MSH|^~\&|LAB|RCH|||201912301150||ORU^R01|4137053|D|2.3|||AL|NE
PID|1||RC00006956|RC6822|LABTEST^JINGLE^||19880615|F||||||||||RC000876/19|9875709808
OBR|1|37336^LAB|00028066^3012:CS00003R^LAB^301219:CS3^37336|523.4906^TBIGS^TB Quantiferon Gold Serology^^^71775-1||201912301041|201912301041|||||||201912301041||||||||||LAB|F||||
OBX|1|ST|523.4910^TBQB^TB Spec Desc^ZQFBDS^XXX-0002^XXX-0002|1|Quantiferon Blood^^N|||N||A^S|F|||201912301043
NTE|1||Pre-analytical processing of this sample was performed by
NTE|2||the submitting site.
NTE|3||Analytical testing was performed by the Zoonotic Diseases
NTE|4||and Emerging Pathogens Program, BC Public Health
NTE|5||Microbiology and Reference laboratory.
OBX|2|ST|523.4922^TBQR1^Quantiferon Plus TB Assay^TBQS^XBC2545-8^XBC2545-8|1|Reactive.^^N|||H||A^S|F|||201912301150
NTE|1||(Enzyme Immunoassay)
NTE|2||M. tuberculosis infection likely when either TB antigen is >= 0.35 IU/mL.
NTE|3||Interpretation of IGRA results should include assessment of TB risk factors and
NTE|4||may include diagnostic imaging. For further consultation please contact
NTE|5||Provincial TB services at 604 707 5678 or fax
NTE|6||referral to 604 707 2690.
OBX|3|ST|523.4932^TBQIU2^Quantiferon PLUS TB1 IU/mL^TBIGS^46217-6^46217-6|1|0.45^^N|IU/mL||N||A^S|F|||201912301150
OBX|4|ST|523.4933^TBQIU3^Quantiferon PLUS TB2 IU/mL^TBIGS^88518-6^88518-6|1|0.54^^N|IU/mL||N||A^S|F|||201912301150

